UroGen awards special bonuses totaling $845K to CEO, CFO, GC for ZUSDURI FDA approval

UroGen Pharma Ltd.

CEO Elizabeth Barrett receives $645,000; CFO Chris Degnan and GC Jason Smith each get $100,000.
Bonuses approved June 30, 2025, for leadership leading to FDA approval of ZUSDURI for recurrent low-grade intermediate risk NMIBC.
ZUSDURI is a novel therapy for non-muscle invasive bladder cancer (NMIBC).
One-time special awards; no recurrence or changes to base compensation.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.